The role of docetaxel based therapy for prostate cancer in the era of targeted medicine

Authors

  • Guru Sonpavde,

    1. Texas Oncology, and
    2. Veterans Affairs Medical Center and the Baylor College of Medicine, Houston, Texas, USA, and
    Search for more papers by this author
  • Cora N Sternberg

    Corresponding author
    1. San Camillo and Forlanini Hospitals, Rome, Italy
      Cora N Sternberg md facp, San Camillo and Forlanini Hospitals, Nuovi Padiglione IV, Circonvallazione Gianicolense 87, 00152 Rome, Italy. Email: csternberg@scamilloforlanini.rm.it; cstern@mclink.it
    Search for more papers by this author

Cora N Sternberg md facp, San Camillo and Forlanini Hospitals, Nuovi Padiglione IV, Circonvallazione Gianicolense 87, 00152 Rome, Italy. Email: csternberg@scamilloforlanini.rm.it; cstern@mclink.it

Abstract

Docetaxel based chemotherapy has been shown to modestly extend life, relieve pain and improve the quality of life in patients with metastatic castration-resistant prostate cancer. Current trials are attempting to build on the backbone of docetaxel by combining it with novel biological agents. Trials are also investigating the role of docetaxel for earlier stages of prostate cancer. No standard second-line systemic therapy exists and such patients are candidates for clinical trials. The increased understanding of the mechanisms of progressive castration-resistant prostate cancer is being translated into an increasing pipeline of novel therapies.

Ancillary